| Literature DB >> 28729528 |
Li Peng1,2, Manman Peng3, Bo Liao1, Guohua Huang4, Wei Liang2, Keqin Li5.
Abstract
MicroRNAs (miRNAs) performs crucial roles in various human diseases, but miRNA-related pathogenic mechanisms remain incompletely understood. Revealing the potential relationship between miRNAs and diseases is a critical problem in biomedical research. Considering limitation of existing computational approaches, we develop improved low-rank matrix recovery (ILRMR) for miRNA-disease association prediction. ILRMR is a global method that can simultaneously prioritize potential association for all diseases and does not require negative samples. ILRMR can also identify promising miRNAs for investigating diseases without any known related miRNA. By integrating miRNA-miRNA similarity information, disease-disease similarity information, and miRNA family information to matrix recovery, ILRMR performs better than other methods in cross validation and case studies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28729528 PMCID: PMC5519594 DOI: 10.1038/s41598-017-06201-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Performance evaluation of ILRMR in two situations based on LOOCV. (1) ILRMR with all information (ILRMR); (2) ILRMR without weight matrix W.
Comparison of prediction performance of ILRMR under different mask ratios.
|
| 0.10 | 0.15 | 0.20 | 0.25 | 0.30 | 0.35 | 0.40 | 0.45 | 0.50 | 0.55 | 0.60 |
|
| 0.9432 | 0.9371 | 0.9280 | 0.9188 | 0.9067 | 0.8846 | 0.8769 | 0.8536 | 0.8301 | 0.8276 | 0.8014 |
Figure 2Comparison of methods between ILRMR, Net-CBI, and RLSMDA in terms of ROC curve and AUC on LOOCV. Without miRNA family and similarity of known miRNA-disease association network under consideration, ILRMR outperformed Net-CBI and RLSMDA in LOOCV.
Figure 3PR curve and AUPR values of ILRMR, RLSMDA and NetCBI.
The top 50 lung cancer-related miRNAs predicted by ILRMR and the confirmation of these associations.
| rank | miRNA name | evidences | rank | miRNA name | evidences |
|---|---|---|---|---|---|
| 1 | hsa-mir-31 | HMDD, dbDEMC, miR2disease | 26 | hsa-mir-204 | miR2disease |
| 2 | hsa-mir-542 | HMDD | 27 | hsa-mir-25 | HMDD, dbDEMC |
| 3 | hsa-mir-222 | HMDD, dbDEMC, miR2disease | 28 | hsa-mir-133a | HMDD, dbDEMC |
| 4 | hsa-mir-494 | HMDD, dbDEMC | 29 | hsa-mir-429 | dbDEMC, miR2disease |
| 5 | hsa-mir-103 | HMDD, dbDEMC | 30 | hsa-mir-339 | dbDEMC, miR2disease |
| 6 | hsa-mir-7 | HMDD, miR2disease | 31 | hsa-mir-127 | HMDD,dbDEMC |
| 7 | hsa-mir-10b | HMDD, dbDEMC | 32 | hsa-mir-215 | dbDEMC |
| 8 | hsa-mir-93 | HMDD, dbDEMC, miR2disease | 33 | hsa-mir-451 | dbDEMC, miR2disease |
| 9 | hsa-mir-221 | HMDD,dbDEMC | 34 | hsa-mir-302c | dbDEMC |
| 10 | hsa-mir-141 | dbDEMC, miR2disease | 35 | hsa-mir-151 | Unconfirmed |
| 11 | hsa-mir-99a | dbDEMC, miR2disease | 36 | hsa-mir-373 | dbDEMC |
| 12 | hsa-mir-296 | dbDEMC | 37 | hsa-mir-130a | dbDEMC, miR2disease |
| 13 | hsa-mir-23a | HMDD, dbDEMC | 38 | hsa-mir-200c | HMDD, dbDEMC, miR2disease |
| 14 | hsa-mir-16 | dbDEMC, miR2disease | 39 | hsa-mir-15b | dbDEMC |
| 15 | hsa-mir-98 | HMDD, dbDEMC, miR2disease | 40 | hsa-mir-18b | HMDD |
| 16 | hsa-mir-488 | dbDEMC | 41 | hsa-mir-135b | HMDD, dbDEMC |
| 17 | hsa-mir-302d | dbDEMC | 42 | hsa-mir-372 | Unconfirmed |
| 18 | hsa-mir-200b | HMDD,dbDEMC, miR2disease | 43 | hsa-mir-27a | HMDD, dbDEMC |
| 19 | hsa-mir-200a | HMDD, dbDEMC, miR2disease | 44 | hsa-mir-423 | miR2disease |
| 20 | hsa-mir-185 | HMDD, dbDEMC | 45 | hsa-mir-22 | HMDD, dbDEMC, miR2disease |
| 21 | hsa-mir-320 | dbDEMC | 46 | hsa-mir-107 | HMDD, dbDEMC |
| 22 | hsa-mir-377 | miR2disease | 47 | hsa-mir-20b | dbDEMC |
| 23 | hsa-mir-195 | dbDEMC, miR2disease | 48 | hsa-mir-376b | Unconfirmed |
| 24 | hsa-mir-181b | HMDD, dbDEMC, miR2disease | 49 | hsa-mir-629 | HMDD |
| 25 | hsa-mir-135a | HMDD, dbDEMC | 50 | hsa-mir-486 | HMDD, dbDEMC |
Forty-seven of the top 50 potential lung cancer miRNAs candidates have been confirmed based on the update HMDD, dbDEMC and mir2disease.
miRNA-disease associations.
| miRNA | disease | |||
|---|---|---|---|---|
|
|
| … |
| |
|
| 0 | 1 | … | 0 |
|
| 1 | 0 | … | 0 |
| … | 0 | 0 | … | 1 |
|
| 1 | 0 | … | 0 |
Figure 4The overall flowchart of ILRMR.